Ocrelizumab: A Deep Dive into IDC-2403's Mechanism Ocrelizumab, initially investigated as IDC-2403, exhibits a specific pathway of operation targeting B cells, critical in the manifestation of several sclerosis & related ailments. It primarily binds to the CD20 antigen expressed on most mature be cells, leading to their elimination via antibody-de